Model for hepatitis C virus transmissions

Elamin H. Elbasha

doi:10.3934/mbe.2013.10.1045

Article Contents

2013, Volume 10, Issue 4: 1045-1065. Doi: 10.3934/mbe.2013.10.1045

This issue Previous Article Darwinian dynamics of a juvenile-adult model Next Article Parametrization of the attainable set for a nonlinear control model of a biochemical process

Model for hepatitis C virus transmissions

Elamin H. Elbasha^1,

1.
Merck Research Laboratories, UG1C-60, PO Box 1000, North Wales, PA 19454-1099

Received: September 30, 2012

Revised: February 28, 2013

Published: May 2013

Abstract Related Papers Cited by

Abstract

Hepatitis C virus (HCV) is a leading cause of chronic liver disease. This paper presents a deterministic model for HCV infection transmission and uses the model to assess the potential impact of antiviral therapy. The model is based on the susceptible-infective-removed-susceptible (SIRS) compartmental structure with chronic primary infection and possibility of reinfection. Important epidemiologic thresholds such as the basic and control reproduction numbers and a measure of treatment impact are derived. We find that if the control reproduction number is greater than unity, there is a locally unstable infection-free equilibrium and a unique, globally asymptotically stable endemic equilibrium. If the control reproduction number is less than unity, the infection-free equilibrium is globally asymptotically stable, and HCV will be eliminated. Numerical simulations suggest that, besides the parameters that determine the basic reproduction number, reinfection plays an important role in HCV transmissions and magnitude of the public health impact of antiviral therapy. Further, treatment regimens with better efficacy holds great promise for lowering the public health burden of HCV disease.

Keywords:

Mathematics Subject Classification: Primary: 34D20, 92D30; Secondary: 65L20, 93C15.

Citation:

Related Papers

Cited by

References

[1]	M. J. Alter, H. S. Margolis, K. Krawczynski, F. N. Judson, A. Mares, W. J. Alexander, P. Y. Hu, J. K. Miller, M. A. Gerber and R. E. Sampliner, The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team, N. Engl. J. Med., 327 (1992), 1899-1905.
[2]	J. J. Amon, R. S. Garfein, L. Ahdieh-Grant, G. L. Armstrong, L. J. Ouellet, M. H. Latka, D. Vlahov, S. A. Strathdee, S. M. Hudson, P. Kerndt, D. Des Jarlais and I. T. Williams, Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004, Clin. Infect. Dis., 46 (2008), 1852-1858.
[3]	D. Amarapurkar, Natural history of hepatitis C virus infection, J. Gastroenterol. Hepatol., 15 (2000), E105-E110.
[4]	R. M. Anderson and R. M. May, "Infectious Diseases of Humans: Dynamics and Control," Oxford University Press, Oxford, 1991.
[5]	G. L. Armstrong, A. Wasley, E. P. Simard, G. M. McQuillan, W. L. Kuhnert and M. J. Alter, The prevalence of hepatitis C virus infection in the United States, 1999 through 2002, Ann. Intern. Med., 144 (2006), 705-714.
[6]	G. L. Armstrong, Injection drug users in the United States, 1979-2002: An aging population, Arch. Intern. Med., 167 (2007), 166-173.
[7]	J. P. Bate, A. J. Colman, P. J. Frost, D. R. Shaw and H. A. J. Harley, High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C, J. Gastroenterol. Hepatol., 25 (2010), 1276-1280.
[8]	W. G. Bennett, Y. Inoue, J. R. Beck, J. B. Wong, S. G. Pauker and G. L. Davis, Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C, Ann. Intern. Med., 127 (1997), 55-65.
[9]	S. M. Blower and H. Dowlatabadi, Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example, Int. Stat. Rev., 62 (1994), 229-243.
[10]	S. Blower, K. Koelle and J. Mills, Health policy modeling: Epidemic control, HIV vaccines, and risky behavior, in "Quantitative Evaluation of HIV Prevention Programs" (Eds. Brookmeyer Kaplan ), (2002), 260-289. Yale University Press, New Haven.
[11]	A. A. Butt, A. C. Justice, M. Skanderson, M. O. Rigsby, C. B. Good and C. K. Kwoh, Rate and predictors of treatment prescription for hepatitis C, Gut, 56 (2007), 385-389.
[12]	Centers for Disease Control and Prevention (CDC), Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease, MMWR Recomm Rep., 47 (1998), 1-39.
[13]	Centers for Disease Control and Prevention (CDC), "Hepatitis C Information for Health Professionals," 2010. (accessed October 5, 2012), http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm\#section1.
[14]	Centers for Disease Control and Prevention (CDC), Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965, Recommendations and Reports, 61 (2012), 1-18.
[15]	O. Dalgard, A. Egeland, K. Skaug, K. Vilimas and T. Steen, Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection, Hepatology, 39 (2004), 74-80.
[16]	A. M. Di Bisceglie, Natural history of hepatitis C: Its impact on clinical management, Hepatology, 31 (2000), 1014-1018.
[17]	P. Das, D. Mukherjee and A. K. Sarkar, Analysis of a disease transmission model of hepatitis C, J. Biol. Sys., 13 (2005), 331-339.
[18]	O. Diekmann, J. A. P. Heesterbeek and J. A. J. Metz, On the definition and the computation of the basic reproduction ratio $R_{0}$ in models for infectious diseases in heterogeneous populations, J. Math. Biol., 28 (1990), 365-382 .doi: 10.1007/BF00178324.
[19]	O. Diekmann, J. A. P. Heesterbeek and M. G. Roberts, The constructions of next-generation matrices fro compartmental epidemiologic models, J. R. Soc. Interface, 7 (2010), 873-885.
[20]	E. Dorey, Competition intensifies around hepatitis C, Nat. Biotechnology, 27 (2009), 305-306.
[21]	K. A. Dowd, R. C. Hershow, S. Yawetz, P. Larussa, C. Diaz, S. H. Landesman, M. E. Paul, J. S. Read, M. Lu, D. L. Thomas, D. M. Netski and S. C. Ray, Maternal neutralizing antibody and transmission of hepatitis C virus to infants, J. Infect. Dis., 198 (2008), 1651-1655.
[22]	E. H. Elbasha, Global stability of equilibria in a two-sex HPV vaccination model, Bull. Math. Biol., 70 (2008), 894-909.doi: 10.1007/s11538-007-9283-0.
[23]	P. Ferenci and K. R. Reddy, Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection, Antivir Ther., 16 (2011), 1187-1201.
[24]	M. G. Ghany, D. B. Strader, D. L. Thomas and L. B. Seeff, Diagnosis, management, and treatment of hepatitis C: an update. American Association for the Study of Liver Diseases, Hepatology, 49 (2009), 1335-1374.
[25]	J. Grebely, B. Conway, J. D. Raffa, C. Lai, M. Krajden and M. W. Tyndall, Hepatitis C virus reinfection in injection drug users, Hepatology, 44 (2006), 1139-1145.
[26]	H. W. Hethcote, The mathematics of infectious diseases, SIAM Rev., 42 (2000), 599-653.doi: 10.1137/S0036144500371907.
[27]	S. Kamal, Acute pepatitis C: A systematic review, Am. J. Gastroenterol, 103 (2008), 1283-1297.
[28]	H. Khalil, "Nonlinear Systems," 3rd edn. Prentice Hall, New York, 2002.
[29]	J. Kimber, L. Copeland, M. Hickman, J. Macleod, J. McKenzie, D. De Angelis and J. R. Robertson, Survival and cessation in injecting drug users: Prospective observational study of outcomes and effect of opiate substitution treatment, BMJ, 341 (2010), c3374.
[30]	W. O. Kermack and A. G. McKendrick, Contributions to the mathematical theory of epidemics, part 1, Proc. Roy. Soc. Lond. A., 115 (1927), 700-721.
[31]	S. H. Kleinman, N. Lelie and M. P. Busch, Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion, Transfusion, 49 (2009), 2454-2489.
[32]	M. Kretzschmar and L. Wiessing, Modelling the transmission of hepatitis C in injecting drug users, in "Hepatitis C and Injecting Drug Use: Impact, Costs and Policy Options" (eds. J. C. Jager, W. Limburg, M. Kretzschmar, M. J. Postma and L. Wiessing), Lisbon: European Monitoring Centre For Drugs And Drug Addiction, (2004).
[33]	M. E. Major, K. Mihalik, M. Puig, B. Rehermann, M. Nascimbeni, C. M. Rice and S. M. Feinstone, Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge, J. Virol., 76 (2002), 6586-6595.
[34]	S. Marino, I. B. Hogue, C. J. Ray and D. E. Kirschner, A methodology for performing global uncertainty and sensitivity analysis in systems biology, J. Theor. Biol., 254 (2008), 178-196.doi: 10.1016/j.jtbi.2008.04.011.
[35]	M. Martcheva and C. Castillo-Chavez, Disease with chronic stage in a population with varying size, Math. Biosci., 182 (2003), 1-25.doi: 10.1016/S0025-5564(02)00184-0.
[36]	C. Matheï, S. Van Dooren, P. Lemey, P. Van Damme, F. Buntinx and A-M. Vandamme, The epidemic history of hepatitis C among injecting drug users in Flanders, Belgium, J. Viral. Hepat., 15 (2008), 399-408.
[37]	S. H. Mehta, B. L. Genberg, J. Astemborski, R. Kavasery, G. D. Kirk, D. Vlahov, S. A. Strathdee and D. L. Thomas, Limited uptake of hepatitis C treatment among injection drug users, J. Community Health, 33 (2008), 126-133.
[38]	A. McLean and S. Blower, Imperfect vaccines and herd immunity to HIV, Proc. Roy. Soc. Lond. B., 253 (1993), 9-13.
[39]	S. H. Mehta, A. Cox, D. R. Hoover, X. H. Wang, Q. Mao, S. Ray, S. A. Strathdee, D. Vlahov and D. L. Thomas, Protection against persistence of hepatitis C, Lancet., 359 (2002), 1478-1483.
[40]	A. U. Neumann, N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden and A. S. Perelson, Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy, Science, 282 (1998), 103-107.
[41]	H. Ohto, S. Terazewa and N. Sasaki, Transmission of hepatitis C virus from mothers to infants, N. Engl. J. Med., 330 (1994), 744-750.
[42]	W. O. Osburn, B. E. Fisher, K. A. Dowd, G. Urban, L. Liu, S. C. Ray, T. L. Thomas and A. L. Cox, Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection, Gastroenterology, 138 (2010), 315-324.
[43]	O. G. Pybus, A. Cochrane, E. C. Holmes and P. Simmonds, The hepatitis C virus epidemic among injecting drug users, Infec. Gene. Evol., 5 (2005), 131-139.
[44]	L. Rong and A. S. Perelson, Treatment of hepatitis C virus infection and small molecule direct antivirals: viral kinetics and modeling, Crit. Rev. Immunol., 30 (2010), 131-148.
[45]	B. H. Singer and D. E. Kirschner, Influence of backward bifurcation on interpretation of $R_{0}$ in a model of epidemic Tuberculosis with reinfection, Math Biosci. Eng., 1 (2004), 81-93.doi: 10.3934/mbe.2004.1.81.
[46]	A. Takaki, M. Wiese, G. Maertens, E. Depla, U. Seifert, A. Liebetrau, J. L. Miller, M. P. Manns and B. Rehermann, Cellular immune responses persist, humoral responses decrease two decades after recovery from a single source outbreak of hepatitis C, Nat. Med., 6 (2000), 578-582.
[47]	P. van den Driessche and J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, Math. Biosci., 180 (2002), 29-48.doi: 10.1016/S0025-5564(02)00108-6.
[48]	M. L. Volk, R. Tocco, S. Saini and A. S. Lok,, Public health impact of antiviral therapy for hepatitis C in the United States, Hepatology, 50 (2009), 1750-1755.
[49]	J. J. Weusten, A. A. van Drimmelen and P. N. Lelie, Mathematical modeling of the risk of HBV, HCV, and HIV transmission by window phase donations not detected by NAT, Transfusion, 42 (2002), 537-548.
[50]	World Health Organization (WHO), "Facts Sheet: Hepatitis C," http://www.who.int/mediacentre/factsheets/fs164/en/index.html (accessed October 29, 2012).
[51]	I. Zeiler, T. Langlands, J. M. Murray and A. Ritter, Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs, Drug Alcohol. Depend., 110 (2010), 228-233.